Genetic Engineering and Biotechnology News

Credit

OncoMed Chooses SynCo to Fill and Finish Its Lead mAb

Cancer compound is scheduled to enter Phase I studies later this year.

SynCo Bio Partners will fill and finish batches of OncoMed Pharmaceuticals’ anticancer mAb OMP-21M18. This is OncoMed’s lead compound and is expected to enter Phase I trials this year.

OncoMed recently inked a deal with GlaxoSmithKline valued at $1.4 billion to advance its cancer stem-cell antibody therapeutics. OMP-21M18, represent a key project in this alliance.

NewsAntibody immunotherapyCancer stem cellsClinical drug developmentDrug development (Research and development)Genetic engineeringGenetic Engineering and BiotechnologyImmunotherapyMedicine, Diagnosis, and TherapeuticsMonoclonal antibody therapyPhase I clinical trials (Drug development)Regenerative engineeringResearch and developmentStem cell engineeringStem cellsTherapeuticsGlaxoSmithKline